Literature DB >> 35192029

Factors associated with diabetic macular edema in patients with proliferative diabetic retinopathy.

John R O'Fee1, Joseph Juliano1, Andrew A Moshfeghi2.   

Abstract

PURPOSE: To identify factors associated with diabetic macular edema (DME) and to characterize the types of DME present in eyes with proliferative diabetic retinopathy (PDR).
METHODS: Observational, retrospective case series of PDR patients reviewed for demographic information, general medical history, ophthalmologic history, optical coherence tomography (OCT), and fluorescein angiogram image characteristics. DME and vitreomacular interface (VMI) status were determined using OCT images. DME was defined as center-involving DME (CI-DME) and noncenter-involving DME (NCI-DME). VMI was defined as vitreomacular adhesion (VMA), vitreomacular traction (VMT), or macular posterior vitreous detachment (PVD).
RESULTS: A total of 293 eyes of 210 screened patients with PDR were included. Of the eyes, 194/293 (66.2%) had DME, and 99/293 (33.8%) had no DME; in univariable analysis, there were no significant differences in VMI status (p = 0.4) or epiretinal membrane (ERM, p = 0.1) between them. Of 194 eyes with DME, 90/194 (46.4%) had CI-DME, and 104/194 (53.6%) had NCI-DME. In univariable analysis, CI-DME eyes were significantly more likely than NCI-DME eyes to have a PVD (p = 0.029) and ERM (p < 0.001). In multivariable analysis, the presence of younger age (p = 0.028) and presence of ERM (p = 0.001) were significantly more likely to be observed in eyes with CI-DME.
CONCLUSION: In this exploratory study focused on diabetic patients with PDR, we determined that VMI status did not have a significant association with DME in general, but VMI status, younger age, and presence of ERM may be associated with CI-DME.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Diabetes; Diabetic macular edema; Proliferative diabetic retinopathy; Vitreoretinal interface

Mesh:

Year:  2022        PMID: 35192029     DOI: 10.1007/s00417-022-05595-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  30 in total

1.  Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema.

Authors:  David Gaucher; Ramin Tadayoni; Ali Erginay; Belkacem Haouchine; Alain Gaudric; Pascale Massin
Journal:  Am J Ophthalmol       Date:  2005-05       Impact factor: 5.258

2.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

3.  Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Shinko Nakamura; Tatsuya Mimura; Shuichiro Eguchi; Hidetaka Noma; Sadao Hori
Journal:  Ophthalmology       Date:  2006-01-10       Impact factor: 12.079

4.  Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

Authors:  Rodrigo Jorge; Rogério A Costa; Daniela Calucci; Léssia P Cintra; Ingrid U Scott
Journal:  Retina       Date:  2006 Nov-Dec       Impact factor: 4.256

5.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.

Authors:  Jeffrey S Heier; Jean-François Korobelnik; David M Brown; Ursula Schmidt-Erfurth; Diana V Do; Edoardo Midena; David S Boyer; Hiroko Terasaki; Peter K Kaiser; Dennis M Marcus; Quan D Nguyen; Glenn J Jaffe; Jason S Slakter; Christian Simader; Yuhwen Soo; Thomas Schmelter; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Carola Metzig; Frank G Holz
Journal:  Ophthalmology       Date:  2016-09-17       Impact factor: 12.079

6.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Neil M Bressler; Susan B Bressler; Alexander J Brucker; Frederick L Ferris; G Robert Hampton; Chirag Jhaveri; Michele Melia; Roy W Beck
Journal:  Ophthalmology       Date:  2016-02-27       Impact factor: 12.079

7.  Association of vitreous inflammatory factors with diabetic macular edema.

Authors:  Hideharu Funatsu; Hidetaka Noma; Tatsuya Mimura; Shuichiro Eguchi; Sadao Hori
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

8.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

9.  Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy.

Authors:  Nader Baharivand; Nosratollah Zarghami; Farid Panahi; M Yazdan Dokht Ghafari; Ali Mahdavi Fard; Abbas Mohajeri
Journal:  Clin Ophthalmol       Date:  2012-01-26

10.  The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey.

Authors:  Durgul Acan; Mehmet Calan; Duygu Er; Tugba Arkan; Nilufer Kocak; Firat Bayraktar; Suleyman Kaynak
Journal:  BMC Ophthalmol       Date:  2018-04-12       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.